Tech Company Financing Transactions
Orasis Pharmaceuticals Funding Round
On 10/8/2024, Orasis Pharmaceuticals announced $78 million in funding from Arboretum Ventures, Johnson & Johnson Innovation and Bluestem Capital.
Transaction Overview
Company Name
Announced On
10/8/2024
Transaction Type
Venture Equity
Amount
$78,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support the commercial launch of Qlosi� (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel corrective eye drop for the treatment of presbyopia in adults.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 Marketside Avenue 404-324
Ponte Vedra, FL 32081
USA
Ponte Vedra, FL 32081
USA
Phone
Undisclosed
Website
Email Address
Overview
Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI� (pilocarpine HCl ophthalmic solution) 0.4%, for presbyopia as an alternative to reading glasses. Presbyopia is the gradual loss of your eye's ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elad Kedar
Chief Medical Officer
Ron Neumann
President
Paul Smith
Vice President
Tes Ignacio
VP - Finance
Yaron Shimon
VP - Manufacturing
Sharon Amzel-Sasson
VP - Marketing
Julie Speed
VP - Regulatory Affairs
Iris Meisner
Browse more venture capital transactions:
Prev: 10/8/2024: Building Radar venture capital transaction
Next: 10/8/2024: Moselle venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs